Does gut microbiota have an impact on the origin of Alzheimer's and Parkinson's disease? – literature review
DOI:
https://doi.org/10.12775/JEHS.2024.57.005Keywords
neurodegenerative diseases, Alzheimer disease, Parkinson's disease, gut microbiotaAbstract
Introduction and purpose:
Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent. It has been observed recently that alterations in the gut microbiota are associated with the onset of neurodegenerative disorders. This research aims to estimate the pathomechanisms and disease courses associated with the gut microbiota that lead to AD and PD development.
Material and methods
The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included Alzheimer’s disease; Parkinson’s disease; gut microbiota; neurodegenerative diseases.
State of knowledge
The advancement of neurodegenerative processes is linked to the varying progressive course of both disorders. There are numerous likely reasons that connect the development of AD and PD and the gut microbiome. These include the hypotheses on inflammation, the decrease in the quantity of bacteria that produce short-chain fatty acids, and hygiene. The researchers' suggested treatment plans for the two illnesses are comparable.
Conclusions
A major influence on the development of neurodegenerative disorders is the gut microbiome. To clarify the precise connections between the gut microbiota and the development of AD and PD, further thorough research is required. More human research is required. Furthermore, it's possible that early interventions, such switching to a Mediterranean diet, are anticipated to lower the risk of AD or PD.
References
Breijyeh Z, Karaman R. Comprehensive review on alzheimer’s disease: causes and treatment. Molecules. 2020;25(24):5789. doi:10.3390/molecules25245789
Dementia. World Health Organization (WHO). Access 27.01.2024. https://www.who.int/news-room/fact-sheets/detail/dementia
Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of alzheimer’s disease. Curr Neuropharmacol. 2020;18(11):1106-1125. doi:10.2174/1570159x18666200528142429
Soria Lopez J, González H, Léger G. Alzheimer's disease. Handb Clin Neurol. 2019;167:.doi: 10.1016/B978-0-12-804766-8.00013-3.
Reich SG, Savitt JM. Parkinson’s disease. Med Clin North Am. 2019;103(2):337-350. doi:10.1016/j.mcna.2018.10.014
Hirayama M, Ohno K. Parkinson’s disease and gut microbiota. Ann Nutr Metab. 2021:1-8. doi:10.1159/000518147
Elsworth JD. Parkinson’s disease treatment: past, present, and future. J Neural Transm. 2020;127(5):785-791. doi:10.1007/s00702-020-02167-1
Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693:128-133. doi:10.1016/j.brainres.2018.03.015
Quigley EM. Microbiota-Brain-Gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17(12). doi:10.1007/s11910-017-0802-6
Ray S, Agarwal P. Depression and anxiety in parkinson disease. Clin Geriatr Med. 2020;36(1):93-104. doi:10.1016/j.cger.2019.09.012
Scheltens P, De Strooper B, Kivipelto M i in. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590. doi:10.1016/s0140-6736(20)32205-4
Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;10(4):a033118. doi:10.1101/cshperspect.a033118
Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research. 2018;7:1161. doi:10.12688/f1000research.14506.1
Chang HY, Sang TK, Chiang AS. Untangling the Tauopathy for Alzheimer’s disease and parkinsonism. J Biomed Sci. 2018;25(1). doi:10.1186/s12929-018-0457-x
Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of alzheimer’s disease. Curr Neuropharmacol. 2020;18(11):1106-1125. doi:10.2174/1570159x18666200528142429
Ubeda-Bañon I, Saiz-Sanchez D, Flores-Cuadrado A i in. The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases. Transl Neurodegener. 2020;9(1). doi:10.1186/s40035-020-00200-7
Generoso JS, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry. 2020. doi:10.1590/1516-4446-2020-0987
Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut microbiota and dysbiosis in alzheimer’s disease: implications for pathogenesis and treatment. Mol Neurobiol. 2020;57(12):5026-5043. doi:10.1007/s12035-020-02073-3
Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and alzheimer’s disease. J Alzheimers Dis. 2017;58(1):1-15. doi:10.3233/jad-161141
Erny D, Hrabě de Angelis AL, Jaitin D i in. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965-977. doi:10.1038/nn.4030
Chen C, Liao J, Xia Y i in. Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut. 2022:gutjnl—2021-326269. doi:10.1136/gutjnl-2021-326269
Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation. 2019;16(1). doi:10.1186/s12974-019-1494-4
Soscia SJ, Kirby JE, Washicosky KJ i in. The alzheimer's disease-associated amyloid β-protein is an antimicrobial peptide. PLoS ONE. 2010;5(3):e9505. doi:10.1371/journal.pone.0009505
Megur A, Baltriukienė D, Bukelskienė V, Burokas A. The microbiota–gut–brain axis and alzheimer’s disease: neuroinflammation is to blame? Nutrients. 2020;13(1):37. doi:10.3390/nu13010037
Zhuang Z, Yang R, Wang W, Qi L, Huang T. Associations between gut microbiota and Alzheimer’s disease, major depressive disorder, and schizophrenia. J Neuroinflammation. 2020;17(1). doi:10.1186/s12974-020-01961-8
Chang CH, Lin CH, Lane HY. D-glutamate and gut microbiota in alzheimer’s disease. Int J Mol Sci. 2020;21(8):2676. doi:10.3390/ijms21082676
He R, Zheng R, Zheng J i in. Causal association between obesity, circulating glutamine levels, and depression: a Mendelian randomization study. J Clin Endocrinol Amp Metab. 2022. doi:10.1210/clinem/dgac707
Hu X, Wang T, Jin F. Alzheimer’s disease and gut microbiota. Sci China Life Sci. 2016;59(10):1006-1023. doi:10.1007/s11427-016-5083-9
Sochocka M, Donskow-Łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The gut microbiome alterations and inflammation-driven pathogenesis of alzheimer’s disease—a critical review. Mol Neurobiol. 2018;56(3):1841-1851. doi:10.1007/s12035-018-1188-4
Qian XH, Song XX, Liu XL, Chen SD, Tang HD. Inflammatory pathways in Alzheimer’s disease mediated by gut microbiota. Ageing Res Rev. 2021;68:101317. doi:10.1016/j.arr.2021.101317
Solch RJ, Aigbogun JO, Voyiadjis AG i in. Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: a systematic review. J Neurol Sci. 2022;434:120166. doi:10.1016/j.jns.2022.120166
Leblhuber F, Egger M, Schuetz B, Fuchs D. Commentary: effect of probiotic supplementation on cognitive function and metabolic status in alzheimer's disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2018;10. doi:10.3389/fnagi.2018.00054
Sun J, Xu J, Ling Y i in. Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice. Transl Psychiatry. 2019;9(1). doi:10.1038/s41398-019-0525-3
Hirayama M, Ohno K. Parkinson’s disease and gut microbiota. Ann Nutr Metab. 2021:1-8. doi:10.1159/000518147
Raka F, Farr S, Kelly J, Stoianov A, Adeli K. Metabolic control via nutrient-sensing mechanisms: role of taste receptors and the gut-brain neuroendocrine axis. Am J Physiol Endocrinol Metab. 2019;317(4):E559—E572. doi:10.1152/ajpendo.00036.2019
Zhang W, Ye Y, Song J i in. Research progress of microbiota-gut-brain axis in parkinson's disease. J Integr Neurosci. 2023;22(6):157. doi:10.31083/j.jin2206157
Aho VT, Pereira PA, Voutilainen S i in. Gut microbiota in Parkinson's disease: temporal stability and relations to disease progression. EBioMedicine. 2019;44:691-707. doi:10.1016/j.ebiom.2019.05.064
Mulak A. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol. 2015;21(37):10609. doi:10.3748/wjg.v21.i37.10609
Boertien JM, Murtomäki K, Pereira PA i in. Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease. NPJ Park Dis. 2022;8(1). doi:10.1038/s41531-022-00395-8
Li X, Feng X, Jiang Z, Jiang Z. Association of small intestinal bacterial overgrowth with Parkinson’s disease: a systematic review and meta-analysis. Gut Pathog. 2021;13(1). doi:10.1186/s13099-021-00420-w
Dănău A, Dumitrescu L, Lefter A, Tulbă D, Popescu BO. Small intestinal bacterial overgrowth as potential therapeutic target in parkinson’s disease. Int J Mol Sci. 2021;22(21):11663. doi:10.3390/ijms222111663
Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of parkinson’s disease in Denmark. Eur J Neurol. 2012;19(6):864-869. doi:10.1111/j.1468-1331.2011.03643.x
Dardiotis E, Tsouris Z, Mentis AF i in. H. pylori and Parkinson’s disease: meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16-24. doi:10.1016/j.clineuro.2018.09.039
Yemula N, Dietrich C, Dostal V, Hornberger M. Parkinson’s disease and the gut: symptoms, nutrition, and microbiota. J Park Dis. 2021:1-15. doi:10.3233/jpd-212707
Zhao Z, Ning J, Bao XQ i in. Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021;9(1). doi:10.1186/s40168-021-01107-9
Du Y, Li Y, Xu X i in. Probiotics for constipation and gut microbiota in Parkinson's disease. Park Amp Relat Disord. 2022;103:92-97. doi:10.1016/j.parkreldis.2022.08.022
Varesi A, Campagnoli LI, Fahmideh F i in. The interplay between gut microbiota and parkinson’s disease: implications on diagnosis and treatment. Int J Mol Sci. 2022;23(20):12289. doi:10.3390/ijms232012289
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Izabela Oleksak, Michał Leśniewski, Iwona Welian-Polus, Karolina Maliszewska, Joanna Ziółkowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 320
Number of citations: 0